GE Healthcare presents data on PET imaging agent

04/11/2010 | Medical News Today

GE Healthcare has undertaken a Phase II trial on PET imaging agent flutemetamol that examined the efficacy of the agent in identifying the patients with clinically probable Alzheimer's disease. Results were to be presented at a conference in Canada. The company also has initiated the agent's Phase III trial program.

View Full Article in:

Medical News Today

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ